CSI Market
Sign In | Register

Chinook Therapeutics Inc (KDNY) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KDNY quarterly Cash Flow →
Examining cash flow movements between Chinook Therapeutics Inc and Dec 31 2018 reveals how Dec 31 2022 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2018)
Operating Activities
Income-187.87
Depreciation & amortization0.00
Amortization of Other Assets1.72
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.26
Share-based Compensation20.05
Income (Loss) from Equity Method Investments3.25
Fair Value of Assets Acquired0.00
Interest Expense-
Increase Decrease In Contract With Customer Liability-
Non Cash Lease Expense-
Depreciation And Amortization Excluding Amortization Of Intangible Assets3.38
Operating Lease Expense6.28
Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability-
Research And Development Expense Paid Through Issuance Of Common Stock-
Change In Fair Values Of Redeemable Convertible Preferred Stock Tranche Liability-
Change In Fair Value Of Contingent Consideration Liability And Contingent Value Rights Liability-
Increase Decrease In Operating Lease Liabilities-
Income taxes4.34
Equity Method Investment, Realized Gain (Loss) on Disposal0.00
Increase (Decrease) in Accounts Receivable8.97
Increase (Decrease) in Accounts Payable1.38
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities16.61
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-3.32
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities7.47
Discontinued operations0.00
Net Cash flow from Operating Activities-117.48
Investing Activities
Capital Expenditures-1.65
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities200.84
Payments to Acquire Marketable Securities-299.18
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-99.99
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock13.25
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-191.86
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents183.80
Capital Expenditures Incurred But Not Yet Paid0.28
Finance Lease Principal Payments-
Proceeds From At Market Sales Agreement Net Of Offering Costs-
Proceeds From Issuance Of Common Stock Pursuant To Subscription Agreements Prior To Merger Net Of Offering Costs-
Proceeds From Issuance Of Common Stock And Accompanying Pre Funded Warrants In Underwritten Public Offering Net Of Issuance Costs113.08
Proceeds From At Market Sales Agreement Net Of Issuance Costs32.89
Payment Of Previously Incurred Issuance Costs Related To Underwritten Public Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities151.43
Effect of exchange rate on cash flow-0.24
Discontinued operations0.00
Free Cash Flow-119.13
Total Cash Flow-66.29
4 historic quarters locked

Sign in to unlock the full Chinook Therapeutics Inc cash flow history.

Sign In Create Free Account

About Chinook Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-039041

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License